Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03843593 · ClinicalTrials.gov registry record
A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery
A clinical trial of Cutaneous Melanoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 38
- Enrollment target
- 3
- Study locations
NCT03843593: Completed study of Cutaneous Melanoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03843593 is a study of Cutaneous Melanoma that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 38 participants, below the 366-participant average among 30 other Cutaneous Melanoma trials with a reported enrollment target (90% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03843593, a study of Cutaneous Melanoma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 38 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to find out what patients consider when deciding whether or not to receive adjuvant treatment, and how patients feel about their decision after one year.
Primary Outcome
Factors considered are gleaned from the Acceptance/Declination Survey
Conditions Studied
Interventions
- BEHAVIORAL Demographics Questionnaire
- BEHAVIORAL Adjuvant Treatment Beliefs Scale10
- BEHAVIORAL Functional Assessment of Cancer Therapy - Melanoma (FACT-M)11
- BEHAVIORAL Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - General (FACIT-TS-G)13
- BEHAVIORAL Decisional Regret14
Study Locations (3)
New York
- Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
New Jersey
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities) - Basking Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2019-02-14 |
| Est. Completion | 2022-12-29 |
What the finished NCT03843593 record still lists
NCT03843593 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 366-participant average among 30 other Cutaneous Melanoma trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Cutaneous Melanoma appearing as the primary indexed condition, and to 5 interventions - of which Demographics Questionnaire is the first listed.
NCT03843593 reports a single indexed study location in New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT03843593 about?
NCT03843593 is a clinical study titled "A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery". The purpose of this study is to find out what patients consider when deciding whether or not to receive adjuvant treatment, and how patients feel about their decision after one year.
What is the current status of trial NCT03843593?
This trial is currently completed. The enrollment target is 38 participants. The study started on 2019-02-14. Estimated completion is 2022-12-29.
What conditions does trial NCT03843593 study?
This clinical trial studies the following conditions: Cutaneous Melanoma.
What interventions are being tested in trial NCT03843593?
The interventions under investigation include: Demographics Questionnaire (BEHAVIORAL), Adjuvant Treatment Beliefs Scale10 (BEHAVIORAL), Functional Assessment of Cancer Therapy - Melanoma (FACT-M)11 (BEHAVIORAL), Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - General (FACIT-TS-G)13 (BEHAVIORAL), Decisional Regret14 (BEHAVIORAL).
Who is sponsoring clinical trial NCT03843593?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03843593 being conducted?
This trial has 3 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03843593's enrollment target sits among peer trials
38 20th of 30 higher than 11 of 30 other Cutaneous Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cutaneous Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma
RECRUITING
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
RECRUITING · Phase 2
-
ACTengine® IMA203 Combined With mRNA-4203
RECRUITING · Phase 1
-
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI